Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02927704
Other study ID # 2011/016
Secondary ID 11102024konya201
Status Completed
Phase N/A
First received October 6, 2016
Last updated October 6, 2016
Start date March 2011
Est. completion date August 2012

Study information

Verified date October 2016
Source Abant Izzet Baysal University
Contact n/a
Is FDA regulated No
Health authority Turkey: Ethics Committee
Study type Observational

Clinical Trial Summary

The aim of this study is to estimate GCF MCP-1 levels of healthy and Aggressive periodontitis (AgP) subjects and to compare MCP-1 levels between Localized AgP (LAgP) and Generalized AgP (GAgP) to establish its predictive value/role for distinguishing LAgP and GAgP development.


Description:

Patients with aggressive periodontitis (AgP) are diagnosed as rapid and severe periodontal destruction commonly in younger systemically healthy individuals (Armitage, 1999). Although periopathogenic bacteria are essential for initiation, this alone does not be responsible for the manifestation and severity of the clinical status/phenotype (Offenbacher et al., 2008), suggesting an imbalance between host and bacterial load (Kinane et al., 2007). Response to bacterial biofilm is determined by the host immune system (Mahanonda and Pichyangkul, 2007, Amano, 2010) in which genetic and enviromental factors modify and may get individuals more susceptible or resistant to the periodontal diseases (Kulkarni and Kinane, 2014).

The role of whether an impaired or a hyperinflammatory host response is responsible for the progression of aggressive periodontitis has been a topic of discussion. Regarding to this topic Shaddox et al. (2016) studied the whole blood specimens collected from LAgP subjects and stimulated with plaque sample generated from healthy or diseased sites. And as a result, LAgP subjects displayed hyperinflammatory response regardless of contents of bacterial stimulus. In an another research hyperinflammatory responders LAgP subjects presented the lowest reductions in clinical parameters, on the contrary low responders showed the highest reductions after treatment (Allin et al., 2016). Similarly Garrison and Nichols (1989) reported that hyper-inflammatory monocyte phenotype can be deterministic in periodontal destruction. In the view of the aforementioned findings, the aim of this study is to estimate GCF MCP-1 levels of healthy and AgP subjects and to compare MCP-1 levels between LAgP and GAgP to establish its predictive value/role for distinguishing LAgP and GAgP development.

A total of 160 subjects including, 80 AgP and 80 age and gender matched periodontally healthy (H) controls were recruited in this cross-sectional study. Clinical periodontal measurements including plaque index (PI), gingival index (GI), proping depth (PD) and clinical attachment loss (CAL) were performed. GCF samples were collected from 160 patients including 50 LAgP, 30 GAgP and 80 H. Volume of GCF samples were measured by an electronic device (Periotron 8000, OroFlow Inc.) and GCF MCP-1 was measured by an enzyme-linked immunosorbent assay "ELISA".


Recruitment information / eligibility

Status Completed
Enrollment 160
Est. completion date August 2012
Est. primary completion date August 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 16 Years and older
Eligibility Inclusion Criteria:

- Periodontally Healthy control group (n: 80) had < 3mm PD, < 2 GI and no signs of interproximal attachment loss and a history of periodontal disease.

- The AgP group included individuals diagnosed with localized AgP (LAgP) or generalized AgP (GAgP) who were otherwise healthy. Periodontal attachment loss =4 mm accompanied by interproximal bone loss without gingival recession not involving more than two permanent teeth, other than the first molars and incisors were diagnosed with LAgP (n: 50); patients with involvement of at least three teeth, other than the first molars and incisors with an attachment loss =4 mm accompanied by interproximal bone loss without gingival recession were diagnosed with GAgP (n: 30).

Exclusion Criteria:

- Patients who have any systemic diseases or conditions that could effect the periodontium

- hepatitis and/or immunodeficiency virus infection

- a history of periodontal treatment and antibiotic therapy within the 6 months

- < 16 teeth in their mouth

- Subjects who had smoked and were ongoing orthodontic treatment were excluded.

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


Intervention

Other:
Gingival crevicular fluid (GCF) sample
Single intervention has been performed for each subject. GCF samples were collected from four multi rooted teeth (premolar/molar) one of in each quadrant including two maxilla and two mandibula by single examiner in conjunction with clinical measurements in this intervention.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Abant Izzet Baysal University Selcuk University

References & Publications (7)

Armitage GC. Periodontal diagnoses and classification of periodontal diseases. Periodontol 2000. 2004;34:9-21. Review. — View Citation

Emingil G, Atilla G, Hüseyinov A. Gingival crevicular fluid monocyte chemoattractant protein-1 and RANTES levels in patients with generalized aggressive periodontitis. J Clin Periodontol. 2004 Oct;31(10):829-34. — View Citation

Gupta M, Chaturvedi R, Jain A. Role of monocyte chemoattractant protein-1 (MCP-1) as an immune-diagnostic biomarker in the pathogenesis of chronic periodontal disease. Cytokine. 2013 Mar;61(3):892-7. doi: 10.1016/j.cyto.2012.12.012. Epub 2013 Jan 30. — View Citation

Kurtis B, Tüter G, Serdar M, Akdemir P, Uygur C, Firatli E, Bal B. Gingival crevicular fluid levels of monocyte chemoattractant protein-1 and tumor necrosis factor-alpha in patients with chronic and aggressive periodontitis. J Periodontol. 2005 Nov;76(11):1849-55. — View Citation

Lee E, Yang YH, Ho YP, Ho KY, Tsai CC. Potential role of vascular endothelial growth factor, interleukin-8 and monocyte chemoattractant protein-1 in periodontal diseases. Kaohsiung J Med Sci. 2003 Aug;19(8):406-15. — View Citation

Thunell DH, Tymkiw KD, Johnson GK, Joly S, Burnell KK, Cavanaugh JE, Brogden KA, Guthmiller JM. A multiplex immunoassay demonstrates reductions in gingival crevicular fluid cytokines following initial periodontal therapy. J Periodontal Res. 2010 Feb;45(1):148-52. doi: 10.1111/j.1600-0765.2009.01204.x. Epub 2009 Jul 8. — View Citation

Tymkiw KD, Thunell DH, Johnson GK, Joly S, Burnell KK, Cavanaugh JE, Brogden KA, Guthmiller JM. Influence of smoking on gingival crevicular fluid cytokines in severe chronic periodontitis. J Clin Periodontol. 2011 Mar;38(3):219-28. doi: 10.1111/j.1600-051X.2010.01684.x. Epub 2010 Dec 29. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Determination of GCF MCP-1 levels in patients with AgP 1 year No
Secondary Measurement of clinical periodontal parameters in patients with AgP and compare between LAgP and GAgP 1 year No
See also
  Status Clinical Trial Phase
Recruiting NCT05043935 - The Effect of Leukocyte and Platelet-rich Fibrin With Antimicrobial Photodynamic Therapy in Aggressive Periodontitis N/A
Terminated NCT01993368 - Analysis of Osteoimmune Interactions Linking Inflammation and Bone Destruction in Aggressive Periodontitis N/A
Completed NCT02282800 - Immunolocalization of 1,25,Dihydroxyvitamin D3 in Aggressive Periodontitis Patients N/A
Recruiting NCT02833285 - B Cell Functions in Periodontitis
Completed NCT02127203 - Nitro-oxidative Stress in Periodontitis N/A
Completed NCT02223702 - Alternative Antibiotic Regime in the Treatment of GAgP Phase 4
Completed NCT03093207 - Omega-3 Fatty Acids Plus Low-dose Aspirin Daily Supplementation in Surgical Therapy to Treat Aggressive Periodontitis Phase 2/Phase 3
Completed NCT03093246 - Omega-3 Plus Low-dose Aspirin Daily Supplementation in Non-surgical Therapy to Treat Aggressive Periodontitis Phase 2/Phase 3
Completed NCT05297084 - Non Surgical Periodontal Treatment Effect on Il-17 and Il-18 in Aggressive Periodontitis
Completed NCT05295576 - Effect of Non Surgical Periodontal Therapy on Inflammatory Markers in Chronic Periodontitis Patients
Completed NCT02969928 - Two Different Antibiotic Agents to Treat Generalized Aggressive Periodontitis Phase 2/Phase 3
Completed NCT02829983 - Clarithromycin as Adjuvant to Periodontal Debridement N/A
Completed NCT02817568 - Frequency Of MCP-1 And CCR2 Gene Polymorphisms And Its Effect On Gene Expression In Patients With AgP N/A
Active, not recruiting NCT04051255 - Influence of Smoking on Clinical, Microbiological and Immunologic Parameters in Patients With Aggressive Periodontitis. N/A
Completed NCT05001919 - Concentrated Growth Factors in Treatment of Intrabony Defects in Localized Aggressive Periodontitis Phase 1/Phase 2
Completed NCT03727620 - Doxycycline in the Treatment of Aggressive Periodontitis Phase 1/Phase 2
Completed NCT04223869 - IL-34 Levels in Various Types of Periodontitis N/A
Completed NCT03034824 - Effects of Er,Cr:YSGG, Diode Lasers on GCF Cytokines Levels N/A
Completed NCT02049008 - Treatment of Aggressive Periodontitis With Repeated Adjunctive Antimicrobial Photodynamic Therapy Phase 4
Recruiting NCT01510808 - The Affect of Orthodontic Treatment on the Periodontal Status of Patients With Aggressive Periodontitis N/A